A recent real-world study has shown that Novo Nordisk’s Wegovy is more effective than Eli Lilly’s Zepbound in reducing cardiovascular risks associated with obesity. This finding emerges in the wake of a previous head-to-head trial where Zepbound demonstrated superior weight loss outcomes compared to Wegovy. The contrasting results highlight the complexities in evaluating the efficacy of obesity medications beyond weight loss alone.
As the obesity treatment market continues to evolve, it is essential for pharma professionals to consider multiple factors, including cardiovascular health, when assessing the value of these therapies. The implications of this study are significant, as they may influence prescribing practices and patient outcomes. With the ongoing competition between these two pharmaceutical giants, further research and real-world evidence will be critical in shaping the future landscape of obesity management.
